際際滷

際際滷Share a Scribd company logo
CBC interpretation (WBC)
Shumoos Abed
PGY-4
PHCC (25/8/2018)
interpretation-of-CBC WBCLYPHMCVHGB.pptx
A&E (25/8/2018)
interpretation-of-CBC WBCLYPHMCVHGB.pptx
interpretation-of-CBC WBCLYPHMCVHGB.pptx
Medical Registerar (25/8/2018)
A&E (10/9/2018)
Referred from rehabilitation clinic to the emergency as a case of sever anemia (6.1 gm/dl)
for blood transfusion
(10/9/2018)
Medical Registerar (10/9/2018)
OGD & colonoscopy showed no cause of GI bleeding
Hematology Consultation (13/9/2018)
Hematology F/U (16/9/2018)
PANCYTOPENIA
Definitions
PANCYTOPENIA:-
Decreases in all peripheral blood lineages
BiCYTOPENIA:-
Decreases in two peripheral blood lineages
LEUKOPENIA:-
Decrease in WBCs count (<4400 cells/microL in most
clinical laboratories)
How to approach
HISTORY EXAMINATION LAB TEST
Hematology
Referral
INITIAL FURTHER
CBC
CMP
Peripheral
smear
Retics Count
Coagulation
profile
Blood grouping
Case based e.g
Bone
marrow
Imaging
Endosco
pies
Less Urgent No referral
Emergency
Neutropenia
Mild  ANC 1000 and <1500 cells/microL
Moderate  ANC 500 and <1000 cells/microL
Severe  ANC <500 cells/microL
Agranulocytosis  ANC <200 cells/microL
Chronic neutropenia  Neutropenia for >3 months
Constitutional neutropenia  Longstanding neutropenia, typically since
childhood
Granulocytopenia  Reduced number of neutrophils, eosinophils, and
basophils
Isolated neutropenia  Neutropenia without associated anemia and/or
thrombocytopenia
Absolute neutrophil count  The absolute neutrophil count (ANC) is the number of
neutrophils plus bands, but does not include metamyelocytes and less mature forms.
ANC = WBC (cells/microL) x percent (PMNs + bands) 歎 100
Mechanisms of PANCYTOPENIA
1. Bone marrow infiltration/replacement
2. Bone marrow aplasia
3. Blood cell destruction or sequestration
Causes of
PANCYTOPENIA
When to repeat CBC?
 If mild and patient is well
 Repeat in 1-2 weeks, and if persistently low after 6 weeks, then
needs further investigation and to refer him to hematology
 If moderate or severe
 If unwell of febrile, urgent referral
 If patient is well, repeat CBC after 2 weeks (safety netting)
QUESTION
ANSWER
HISTORY
 Time course and clinical severity
 Symptoms associated with pancytopenia
 Recurrent, severe, or unusual infections Fatigue, dyspnea, chest pain,
hemodynamic instability, or claudication due to anemia
 Bleeding or easy bruising
 Fever, night sweats, and/or weight loss
 Nausea, vomiting, and jaundice that may be associated with liver disease
 Previous treatments
 Other medical conditions
 Problematic medications
 Personal and occupational exposures
 Rashes that may be related to drug reactions, rheumatologic disorders,
infections, and malignancies
 Oral lesions; as examples, thrush suggests immune compromise; oral
ulcers may be seen in diseases such as systemic lupus erythematosus
 Lymphadenopathy and/or splenomegaly
 Jaundice and stigmata of liver disease
EXAMINATION
Hematology
Referral
Emergency
Not usually clinically significant
Lymphocytopenia
Normal range 1.0-4.0 X 109
/L
It represents 20-40%
interpretation-of-CBC WBCLYPHMCVHGB.pptx
19-year-old male, not known to have any chronic illnesess
presented to the clinic with generalized weakness, backache,
and significant weight loss for the past 2 years. He was taking
B12 and folic acid plus Iron as supplementations for 2 months
prior to presentation.
On examination
Mild pallor, massive splenomegaly to the level of the umbilicus,
and mild hepatomegaly
interpretation-of-CBC WBCLYPHMCVHGB.pptx
Leukocytosis refers to elevated WBC (leukocyte) count. Neutrophilia is the
most common type of leukocytosis, but leukocytosis may also be due to
increased monocytes, eosinophils, basophils, and/or lymphocytes
Granulocytosis is often used interchangeably with neutrophilia, but
granulocytosis is a broader term that can also reflect increased eosinophils or
basophils.
Left shift is an ill-defined term that refers to an increase in the percentage of
band forms, generally accompanied by metamyelocytes and myelocytes.
Leukemoid reaction refers to WBC >50,000/microL from causes other than
leukemia, with the majority being mature neutrophils, often accompanied by
increased numbers of bands, metamyelocytes, and/or myelocytes
LEUKOCYTOSIS
Approach to the patient with neutrophilia
HISTORY EXAMINATION LAB TEST Special Testing
CBC
Peripheral Smear
 Active or prior infection or inflammation
 Hematologic malignancies
 Surgical or functional asplenia
 Cigarette smoking
 Vigorous exercise
 Extreme physical or emotional distress
 Conditions that may be associated with neutrophilia (eg,
pregnancy, eclampsia, post-partum, thyroid storm,
hypercortisolism)
 Family history
Bone marrow aspirate and biopsy
Flow cytometry
Molecular/genetic testing
How to differentiate between Leukemoid reaction and CML ?
 The LAPscore is raised in Leukemoid reaction whereas
decreased in CML
 Presence of left shift in CML
 Prominence of Myelocytes in CML
 May be Eosinphilia and/or Basophilia in CML
QUESTION
ANSWER
MECHANISMS
Increased production of neutrophils
 Autonomous (ie, due to malignant disorders such as
myeloproliferative neoplasms)
 Reactive (ie, in response to infectious or inflammatory
processes)
CAUSES
OF
NEUTROPHILIA
How to follow a patient with an isolated neutrophilia ?
 If patient is well
 1-2 months, then 3 monthly for 12 months.
 Stop monitoring if normal
QUESTION
ANSWER
Lymphocytosis
Normal range 1.0-4.0 X 109
/L
It represents 20-40%
EOSINOPHILIA
Referral tot hematologist if eosinophilia (moderate, marked) is persistently high for more than
6 months
BASOPHILIA
Normal range 0.0 - 0.2 X 109
/L
Because it is vey rarely be significantly raised, a repeat CBC 1-2 weeks may help

More Related Content

Similar to interpretation-of-CBC WBCLYPHMCVHGB.pptx (20)

Heme talk 10 29-15- dr james
Heme talk 10 29-15- dr  jamesHeme talk 10 29-15- dr  james
Heme talk 10 29-15- dr james
derosaMSKCC
Approach to Anemia.pptx
Approach to Anemia.pptxApproach to Anemia.pptx
Approach to Anemia.pptx
Abhishek Singhai
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdfantiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
SayaliPatil790915
APPROACH TO proteinuriaHEMATURIA (1).pptx
APPROACH TO proteinuriaHEMATURIA (1).pptxAPPROACH TO proteinuriaHEMATURIA (1).pptx
APPROACH TO proteinuriaHEMATURIA (1).pptx
RAMJIBANYADAV2
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
Lord Ceasar
Approac h to cholestatic jaundice
Approac h to cholestatic jaundiceApproac h to cholestatic jaundice
Approac h to cholestatic jaundice
Arun Karmakar
2. GIT CONDITIONS.pptx
2. GIT CONDITIONS.pptx2. GIT CONDITIONS.pptx
2. GIT CONDITIONS.pptx
RaphaelChitalima
APS.pptx
APS.pptxAPS.pptx
APS.pptx
Marwa Khalifa
bsconco.pptxv jwuege83bw eiegrir wiegejrj
bsconco.pptxv jwuege83bw eiegrir wiegejrjbsconco.pptxv jwuege83bw eiegrir wiegejrj
bsconco.pptxv jwuege83bw eiegrir wiegejrj
AshishS82
Haematuria
HaematuriaHaematuria
Haematuria
Dr Subodh Shah
Antiphospholipid Syndrome
Antiphospholipid SyndromeAntiphospholipid Syndrome
Antiphospholipid Syndrome
Waleed El-Refaey
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptxChronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
mmamaobongetefia
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptxChronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
mmamaobongetefia
LIVER ABSCESS-1_withMarginNotes.pdf
LIVER ABSCESS-1_withMarginNotes.pdfLIVER ABSCESS-1_withMarginNotes.pdf
LIVER ABSCESS-1_withMarginNotes.pdf
Mohit Tripathi
CHP-25-diagnostic-testing-wecompress.com_.pdf
CHP-25-diagnostic-testing-wecompress.com_.pdfCHP-25-diagnostic-testing-wecompress.com_.pdf
CHP-25-diagnostic-testing-wecompress.com_.pdf
michaelmakasare14
Practical approach to fever with altered liver functions
Practical approach to fever with altered liver functionsPractical approach to fever with altered liver functions
Practical approach to fever with altered liver functions
ikramdr01
upper G I Bleed (non variceal)
upper G I Bleed (non variceal)upper G I Bleed (non variceal)
upper G I Bleed (non variceal)
Juned Khan
Kidney diseases by Harrison Mbohe
Kidney diseases by Harrison MboheKidney diseases by Harrison Mbohe
Kidney diseases by Harrison Mbohe
HarrisonMbohe
Childhood acute lympocytic leukemia
Childhood acute lympocytic leukemiaChildhood acute lympocytic leukemia
Childhood acute lympocytic leukemia
Vedaste HAKORIMANA
medicine.Myeloproliferative.(dr.sabir)
medicine.Myeloproliferative.(dr.sabir)medicine.Myeloproliferative.(dr.sabir)
medicine.Myeloproliferative.(dr.sabir)
student
Heme talk 10 29-15- dr james
Heme talk 10 29-15- dr  jamesHeme talk 10 29-15- dr  james
Heme talk 10 29-15- dr james
derosaMSKCC
Approach to Anemia.pptx
Approach to Anemia.pptxApproach to Anemia.pptx
Approach to Anemia.pptx
Abhishek Singhai
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdfantiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
antiphospholipidsyndrome-141014120624-conversion-gate01 (1).pdf
SayaliPatil790915
APPROACH TO proteinuriaHEMATURIA (1).pptx
APPROACH TO proteinuriaHEMATURIA (1).pptxAPPROACH TO proteinuriaHEMATURIA (1).pptx
APPROACH TO proteinuriaHEMATURIA (1).pptx
RAMJIBANYADAV2
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
Lord Ceasar
Approac h to cholestatic jaundice
Approac h to cholestatic jaundiceApproac h to cholestatic jaundice
Approac h to cholestatic jaundice
Arun Karmakar
bsconco.pptxv jwuege83bw eiegrir wiegejrj
bsconco.pptxv jwuege83bw eiegrir wiegejrjbsconco.pptxv jwuege83bw eiegrir wiegejrj
bsconco.pptxv jwuege83bw eiegrir wiegejrj
AshishS82
Antiphospholipid Syndrome
Antiphospholipid SyndromeAntiphospholipid Syndrome
Antiphospholipid Syndrome
Waleed El-Refaey
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptxChronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
mmamaobongetefia
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptxChronic Myeloid Leukaemia 18.09.23 updated.pptx
Chronic Myeloid Leukaemia 18.09.23 updated.pptx
mmamaobongetefia
LIVER ABSCESS-1_withMarginNotes.pdf
LIVER ABSCESS-1_withMarginNotes.pdfLIVER ABSCESS-1_withMarginNotes.pdf
LIVER ABSCESS-1_withMarginNotes.pdf
Mohit Tripathi
CHP-25-diagnostic-testing-wecompress.com_.pdf
CHP-25-diagnostic-testing-wecompress.com_.pdfCHP-25-diagnostic-testing-wecompress.com_.pdf
CHP-25-diagnostic-testing-wecompress.com_.pdf
michaelmakasare14
Practical approach to fever with altered liver functions
Practical approach to fever with altered liver functionsPractical approach to fever with altered liver functions
Practical approach to fever with altered liver functions
ikramdr01
upper G I Bleed (non variceal)
upper G I Bleed (non variceal)upper G I Bleed (non variceal)
upper G I Bleed (non variceal)
Juned Khan
Kidney diseases by Harrison Mbohe
Kidney diseases by Harrison MboheKidney diseases by Harrison Mbohe
Kidney diseases by Harrison Mbohe
HarrisonMbohe
Childhood acute lympocytic leukemia
Childhood acute lympocytic leukemiaChildhood acute lympocytic leukemia
Childhood acute lympocytic leukemia
Vedaste HAKORIMANA
medicine.Myeloproliferative.(dr.sabir)
medicine.Myeloproliferative.(dr.sabir)medicine.Myeloproliferative.(dr.sabir)
medicine.Myeloproliferative.(dr.sabir)
student

Recently uploaded (20)

3. coronary circulation.pptx cardiovascular
3. coronary circulation.pptx cardiovascular3. coronary circulation.pptx cardiovascular
3. coronary circulation.pptx cardiovascular
Pooja Rani
BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
BIOMECHANICS  OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptxBIOMECHANICS  OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
drnidhimnd
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
alokksharma18
4. Cardiac cycle.pptx cardiovascular system
4. Cardiac cycle.pptx cardiovascular system4. Cardiac cycle.pptx cardiovascular system
4. Cardiac cycle.pptx cardiovascular system
Pooja Rani
IMMUNO-ONCOLOGY DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
IMMUNO-ONCOLOGY  DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINEIMMUNO-ONCOLOGY  DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
IMMUNO-ONCOLOGY DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
RelianceNwosu
MLS 208 - UNIT 4 A - Tissue Processing - ETANDO AYUK - SANU 1 - Secured.pdf
MLS 208 -  UNIT  4 A  -  Tissue Processing  - ETANDO AYUK - SANU 1 - Secured.pdfMLS 208 -  UNIT  4 A  -  Tissue Processing  - ETANDO AYUK - SANU 1 - Secured.pdf
MLS 208 - UNIT 4 A - Tissue Processing - ETANDO AYUK - SANU 1 - Secured.pdf
Eswatini Medical Christian University - EMCU / Southern Nazarene University - SANU
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
Dr. Anindya
Best Sampling Practices Webinar USP <797> Compliance & Environmental Monito...
Best Sampling Practices Webinar  USP <797> Compliance & Environmental Monito...Best Sampling Practices Webinar  USP <797> Compliance & Environmental Monito...
Best Sampling Practices Webinar USP <797> Compliance & Environmental Monito...
NuAire
MLS 208 - UNIT 1- Lecture Notes - ETANDO AYUK - SANU - Secured.pdf
MLS 208 -  UNIT 1-  Lecture Notes - ETANDO AYUK - SANU - Secured.pdfMLS 208 -  UNIT 1-  Lecture Notes - ETANDO AYUK - SANU - Secured.pdf
MLS 208 - UNIT 1- Lecture Notes - ETANDO AYUK - SANU - Secured.pdf
Eswatini Medical Christian University - EMCU / Southern Nazarene University - SANU
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
ABHAY INSTITUTION
bacterial-genetics-variation-new (1).pptx
bacterial-genetics-variation-new (1).pptxbacterial-genetics-variation-new (1).pptx
bacterial-genetics-variation-new (1).pptx
Dauda Yahaya masani
Eye assessment in polytrauma for undergraduates.pptx
Eye assessment in polytrauma for undergraduates.pptxEye assessment in polytrauma for undergraduates.pptx
Eye assessment in polytrauma for undergraduates.pptx
KafrELShiekh University
Cardiac Arrhythmias for paramedical students.
Cardiac Arrhythmias for paramedical students.Cardiac Arrhythmias for paramedical students.
Cardiac Arrhythmias for paramedical students.
helanmariaarockkiasa
Local Anesthetic Use in the Vulnerable Patients
Local Anesthetic Use in the Vulnerable PatientsLocal Anesthetic Use in the Vulnerable Patients
Local Anesthetic Use in the Vulnerable Patients
Reza Aminnejad
patho neuro block 3 QUESTION AANSWER PDF
patho neuro block 3 QUESTION AANSWER PDFpatho neuro block 3 QUESTION AANSWER PDF
patho neuro block 3 QUESTION AANSWER PDF
HariPrashadL
The influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcomeThe influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcome
Lokesh Kumar Sharma
Optimization in Pharmaceutical Formulations: Concepts, Methods & Applications
Optimization in Pharmaceutical Formulations: Concepts, Methods & ApplicationsOptimization in Pharmaceutical Formulations: Concepts, Methods & Applications
Optimization in Pharmaceutical Formulations: Concepts, Methods & Applications
KHUSHAL CHAVAN
Endocarditis.pptx
Endocarditis.pptxEndocarditis.pptx
Endocarditis.pptx
Nandish Sannaiah
Stability of Dosage Forms as per ICH Guidelines
Stability of Dosage Forms as per ICH GuidelinesStability of Dosage Forms as per ICH Guidelines
Stability of Dosage Forms as per ICH Guidelines
KHUSHAL CHAVAN
Flag Screening in Physiotherapy Examination.pptx
Flag Screening in Physiotherapy Examination.pptxFlag Screening in Physiotherapy Examination.pptx
Flag Screening in Physiotherapy Examination.pptx
BALAJI SOMA
3. coronary circulation.pptx cardiovascular
3. coronary circulation.pptx cardiovascular3. coronary circulation.pptx cardiovascular
3. coronary circulation.pptx cardiovascular
Pooja Rani
BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
BIOMECHANICS  OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptxBIOMECHANICS  OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptx
drnidhimnd
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...
alokksharma18
4. Cardiac cycle.pptx cardiovascular system
4. Cardiac cycle.pptx cardiovascular system4. Cardiac cycle.pptx cardiovascular system
4. Cardiac cycle.pptx cardiovascular system
Pooja Rani
IMMUNO-ONCOLOGY DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
IMMUNO-ONCOLOGY  DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINEIMMUNO-ONCOLOGY  DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
IMMUNO-ONCOLOGY DESCOVERING THE IMPORTANCE OF CLINICAL IMUNOLOGY IN MEDICINE
RelianceNwosu
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
SAPIENT Medi-trivia Quiz (FINALS) | TRI-ORTA 2025
Dr. Anindya
Best Sampling Practices Webinar USP <797> Compliance & Environmental Monito...
Best Sampling Practices Webinar  USP <797> Compliance & Environmental Monito...Best Sampling Practices Webinar  USP <797> Compliance & Environmental Monito...
Best Sampling Practices Webinar USP <797> Compliance & Environmental Monito...
NuAire
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
ABHAY INSTITUTION
bacterial-genetics-variation-new (1).pptx
bacterial-genetics-variation-new (1).pptxbacterial-genetics-variation-new (1).pptx
bacterial-genetics-variation-new (1).pptx
Dauda Yahaya masani
Eye assessment in polytrauma for undergraduates.pptx
Eye assessment in polytrauma for undergraduates.pptxEye assessment in polytrauma for undergraduates.pptx
Eye assessment in polytrauma for undergraduates.pptx
KafrELShiekh University
Cardiac Arrhythmias for paramedical students.
Cardiac Arrhythmias for paramedical students.Cardiac Arrhythmias for paramedical students.
Cardiac Arrhythmias for paramedical students.
helanmariaarockkiasa
Local Anesthetic Use in the Vulnerable Patients
Local Anesthetic Use in the Vulnerable PatientsLocal Anesthetic Use in the Vulnerable Patients
Local Anesthetic Use in the Vulnerable Patients
Reza Aminnejad
patho neuro block 3 QUESTION AANSWER PDF
patho neuro block 3 QUESTION AANSWER PDFpatho neuro block 3 QUESTION AANSWER PDF
patho neuro block 3 QUESTION AANSWER PDF
HariPrashadL
The influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcomeThe influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcome
Lokesh Kumar Sharma
Optimization in Pharmaceutical Formulations: Concepts, Methods & Applications
Optimization in Pharmaceutical Formulations: Concepts, Methods & ApplicationsOptimization in Pharmaceutical Formulations: Concepts, Methods & Applications
Optimization in Pharmaceutical Formulations: Concepts, Methods & Applications
KHUSHAL CHAVAN
Stability of Dosage Forms as per ICH Guidelines
Stability of Dosage Forms as per ICH GuidelinesStability of Dosage Forms as per ICH Guidelines
Stability of Dosage Forms as per ICH Guidelines
KHUSHAL CHAVAN
Flag Screening in Physiotherapy Examination.pptx
Flag Screening in Physiotherapy Examination.pptxFlag Screening in Physiotherapy Examination.pptx
Flag Screening in Physiotherapy Examination.pptx
BALAJI SOMA

interpretation-of-CBC WBCLYPHMCVHGB.pptx

  • 8. A&E (10/9/2018) Referred from rehabilitation clinic to the emergency as a case of sever anemia (6.1 gm/dl) for blood transfusion
  • 10. Medical Registerar (10/9/2018) OGD & colonoscopy showed no cause of GI bleeding
  • 14. Definitions PANCYTOPENIA:- Decreases in all peripheral blood lineages BiCYTOPENIA:- Decreases in two peripheral blood lineages LEUKOPENIA:- Decrease in WBCs count (<4400 cells/microL in most clinical laboratories)
  • 15. How to approach HISTORY EXAMINATION LAB TEST Hematology Referral INITIAL FURTHER CBC CMP Peripheral smear Retics Count Coagulation profile Blood grouping Case based e.g Bone marrow Imaging Endosco pies Less Urgent No referral Emergency
  • 16. Neutropenia Mild ANC 1000 and <1500 cells/microL Moderate ANC 500 and <1000 cells/microL Severe ANC <500 cells/microL Agranulocytosis ANC <200 cells/microL Chronic neutropenia Neutropenia for >3 months Constitutional neutropenia Longstanding neutropenia, typically since childhood Granulocytopenia Reduced number of neutrophils, eosinophils, and basophils Isolated neutropenia Neutropenia without associated anemia and/or thrombocytopenia
  • 17. Absolute neutrophil count The absolute neutrophil count (ANC) is the number of neutrophils plus bands, but does not include metamyelocytes and less mature forms. ANC = WBC (cells/microL) x percent (PMNs + bands) 歎 100
  • 18. Mechanisms of PANCYTOPENIA 1. Bone marrow infiltration/replacement 2. Bone marrow aplasia 3. Blood cell destruction or sequestration
  • 20. When to repeat CBC? If mild and patient is well Repeat in 1-2 weeks, and if persistently low after 6 weeks, then needs further investigation and to refer him to hematology If moderate or severe If unwell of febrile, urgent referral If patient is well, repeat CBC after 2 weeks (safety netting) QUESTION ANSWER
  • 21. HISTORY Time course and clinical severity Symptoms associated with pancytopenia Recurrent, severe, or unusual infections Fatigue, dyspnea, chest pain, hemodynamic instability, or claudication due to anemia Bleeding or easy bruising Fever, night sweats, and/or weight loss Nausea, vomiting, and jaundice that may be associated with liver disease Previous treatments Other medical conditions Problematic medications Personal and occupational exposures
  • 22. Rashes that may be related to drug reactions, rheumatologic disorders, infections, and malignancies Oral lesions; as examples, thrush suggests immune compromise; oral ulcers may be seen in diseases such as systemic lupus erythematosus Lymphadenopathy and/or splenomegaly Jaundice and stigmata of liver disease EXAMINATION
  • 24. Not usually clinically significant Lymphocytopenia Normal range 1.0-4.0 X 109 /L It represents 20-40%
  • 26. 19-year-old male, not known to have any chronic illnesess presented to the clinic with generalized weakness, backache, and significant weight loss for the past 2 years. He was taking B12 and folic acid plus Iron as supplementations for 2 months prior to presentation. On examination Mild pallor, massive splenomegaly to the level of the umbilicus, and mild hepatomegaly
  • 28. Leukocytosis refers to elevated WBC (leukocyte) count. Neutrophilia is the most common type of leukocytosis, but leukocytosis may also be due to increased monocytes, eosinophils, basophils, and/or lymphocytes Granulocytosis is often used interchangeably with neutrophilia, but granulocytosis is a broader term that can also reflect increased eosinophils or basophils. Left shift is an ill-defined term that refers to an increase in the percentage of band forms, generally accompanied by metamyelocytes and myelocytes. Leukemoid reaction refers to WBC >50,000/microL from causes other than leukemia, with the majority being mature neutrophils, often accompanied by increased numbers of bands, metamyelocytes, and/or myelocytes LEUKOCYTOSIS
  • 29. Approach to the patient with neutrophilia HISTORY EXAMINATION LAB TEST Special Testing CBC Peripheral Smear Active or prior infection or inflammation Hematologic malignancies Surgical or functional asplenia Cigarette smoking Vigorous exercise Extreme physical or emotional distress Conditions that may be associated with neutrophilia (eg, pregnancy, eclampsia, post-partum, thyroid storm, hypercortisolism) Family history Bone marrow aspirate and biopsy Flow cytometry Molecular/genetic testing
  • 30. How to differentiate between Leukemoid reaction and CML ? The LAPscore is raised in Leukemoid reaction whereas decreased in CML Presence of left shift in CML Prominence of Myelocytes in CML May be Eosinphilia and/or Basophilia in CML QUESTION ANSWER
  • 31. MECHANISMS Increased production of neutrophils Autonomous (ie, due to malignant disorders such as myeloproliferative neoplasms) Reactive (ie, in response to infectious or inflammatory processes)
  • 33. How to follow a patient with an isolated neutrophilia ? If patient is well 1-2 months, then 3 monthly for 12 months. Stop monitoring if normal QUESTION ANSWER
  • 34. Lymphocytosis Normal range 1.0-4.0 X 109 /L It represents 20-40%
  • 35. EOSINOPHILIA Referral tot hematologist if eosinophilia (moderate, marked) is persistently high for more than 6 months
  • 36. BASOPHILIA Normal range 0.0 - 0.2 X 109 /L Because it is vey rarely be significantly raised, a repeat CBC 1-2 weeks may help